Comparing the current results to its competitors, Femasys Inc reported Revenue decrease in the 2 quarter 2026 year on year by -18.92 %, despite the revenue increase by the most of its competitors of 12.72 %, recorded in the same quarter.
Femasys Inc 's Comment on Competition and Industry Peers
The company operates in highly competitive markets characterized by rapid technological changes. Its permanent birth control solution competes with surgical tubal ligation, vasectomies, and non-permanent contraceptive methods such as IUDs, birth control pills, injectable and implantable contraceptives, and patches. Currently, there is no directly competing non-surgical, non-implant permanent birth control product on the market or known to be in development. For its artificial insemination solution, competitors include intrauterine insemination (IUI), in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), and fertility-enhancing pharmaceuticals. Leading companies producing IUI devices include Cook Medical LLC (a subsidiary of Cook Group, Inc.), Cooper Surgical, Inc., MedGyn Products, Inc., and Rocket Medical LLC. For its tissue sampling product, established competing procedures include the Pap test, HPV test, and colposcopy.
March 6, 2024
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution, Paving the Way Forward for Broader Availability and Cost-Effective Alternatives to IVFIn a significant milestone for reproductive medicine, Femasys, a pioneering healthcare company focused on women s health, recently achieved a groundbreaking feat by successfully completing the first in-office commercial procedure using their FDA-cleared FemaSeed Infertility Solution. This achievement not only reinforces Femasys commitment to developing innovative solutions but also offers hope to countless individuals struggling with infertility.FemaSeed, an accessible, safe, and cost-effective alternative to in v...
February 28, 2024
Femasys FemaSeed: A Timely Solution in the Face of IVF UncertaintyIn recent years, infertility has become a growing concern around the world, affecting millions of couples who dream of starting a family. In the United States alone, it is estimated that one in eight couples struggle with infertility. For decades, in vitro fertilization (IVF) has been the go-to option for those seeking assistance in conceiving, but recent events have thrown this commonly used method into question. However, hope may be on the horizon with the FDA clearance of Femasys FemaSeed, offering a new alternative for individuals facing infertility challenges.IVF has been a revolutionary technique in helping couples conceive, but a recent...
January 23, 2024
In recent developments, Femasys Inc. has launched its pivotal trial for FemBloc - a revolutionary medical device aimed at providing a minimally invasive and reversible contraceptive solution for women. The trial s enrollment is being carried out at the University of Utah, renowned for its expertise in Obstetrics and Gynecology. Dr. Lori Gawron, an esteemed investigator from the Department of Obstetrics and Gynecology at the University of Utah Hospital, played a significant role in Femasys earlier FemBloc study. This article aims to present a comprehensive overview of the facts surrounding this crucial trial.Background:Contraceptive methods have evolved significantly, offering women various choices over the ...
Femasys Inc., a leading medical technology company, has recently achieved a significant milestone by completing the enrollment of the FemaSeed pivotal trial. This achievement positions the company for a successful commercial launch, with topline results from the trial expected to be announced in the first half of 2024. This pivotal trial is a crucial step in demonstrating the effectiveness and safety of FemaSeed, an innovative medical device aimed at addressing fertility challenges faced by millions of couples worldwide. The completion of enrollment for the FemaSeed pivotal trial marks a major advancement for Femasys Inc. This trial will provide crucial data to support the device s commercial l...
West Pharmaceutical Services Inc Share Performance
+7.48%
This Quarter
West Pharmaceutical Services Inc
Profile
West Pharmaceutical Services Inc operates as a global manufacturer and supplier of innovative packaging and delivery systems for the pharmaceutical and biotech sectors. Their business model focuses on providing comprehensive solutions, including drug administration systems and customer support, to ensure safe and efficient delivery of medications to patients.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Masimo Corp is a medical technology company that focuses on developing and manufacturing innovative monitoring devices for patient care. Their business model revolves around creating and selling advanced noninvasive monitoring solutions to healthcare providers worldwide. They also generate revenue through licensing agreements, providing maintenance and support services, and selling disposable products and accessories related to their monitoring devices.
Lucid Diagnostics Inc is a healthcare company that operates with a business model focused on developing and providing innovative diagnostic solutions for the early detection and prevention of diseases, aimed at improving patient outcomes and reducing healthcare costs. They leverage advanced technologies and medical expertise to deliver accurate and reliable diagnostic services to healthcare providers, enabling better decision-making and personalized treatment plans for patients.
Lensar Inc is a medical technology company that operates through a business model focused on the development and commercialization of advanced laser systems for ophthalmic procedures. They aim to provide innovative solutions to healthcare professionals in order to enhance precision, safety, and efficiency in eye surgeries.
Sources:
Femasys Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Femasys Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
